Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Hofer

Showing results (91-100 of 135) with videos related to

Pageof 14
Sort By:
Journal of Psychopharmacology (Oxford, England)|October 20, 2006
Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week studyMaria A Rettenbacher, Martina Hummer, Alex Hofer, et al.
International Clinical Psychopharmacology|October 3, 2006
Early changes of plasma lipids during treatment with atypical antipsychoticsMaria A Rettenbacher, Christoph Ebenbichler, Alex Hofer, et al.
Schizophrenia Research|July 15, 2009
Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophreniaMonika Edlinger, Alex Hofer, Maria A Rettenbacher, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|September 21, 2005
Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effectsAlex Hofer, Susanne Baumgartner, Monika Edlinger, et al.
Frontiers in Psychiatry|November 16, 2020
Premorbid Social Functioning and Affective Symptoms Predict Subjective Outcome Among Outpatients With SchizophreniaChristine M Hoertnagl, Alexandra Kaufmann, Nursen Yalcin-Siedentopf, et al.
Psychopharmacology|September 20, 2024
Exploring the role of orexins in the modulation of social rewardInês M Amaral, Sara Ouaidat, Laura Scheffauer, et al.
Bjpsych Open|September 23, 2024
Investigating patient eligibility for anti-amyloid monoclonal antibody treatment of Alzheimer's disease: real-world data from an Austrian psychiatric memory clinic populationMichaela Defrancesco, Elke R Gizewski, Stephanie Mangesius, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|August 19, 2025
Subjective well-being in early-phase schizophrenia patients using long-acting injectable versus oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)Anna-Theresa Schulze, Timo Schurr, Fabienne Post, et al.
The American Journal of Psychiatry|December 31, 2004
Osteoporosis in patients with schizophreniaMartina Hummer, Peter Malik, Rudolf W Gasser, et al.
Archives of Women'S Mental Health|October 15, 2020
Sex matters: stress perception and the relevance of resilience and perceived social support in emerging adultsNursen Yalcin-Siedentopf, Theresia Pichler, Anna-Sophia Welte, et al.
Pageof 14

Showing results (91-100 of 135) with videos related to

Sort By:
Pageof 14
Journal of Psychopharmacology (Oxford, England)|October 20, 2006
Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week studyMaria A Rettenbacher, Martina Hummer, Alex Hofer, et al.
International Clinical Psychopharmacology|October 3, 2006
Early changes of plasma lipids during treatment with atypical antipsychoticsMaria A Rettenbacher, Christoph Ebenbichler, Alex Hofer, et al.
Schizophrenia Research|July 15, 2009
Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophreniaMonika Edlinger, Alex Hofer, Maria A Rettenbacher, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|September 21, 2005
Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effectsAlex Hofer, Susanne Baumgartner, Monika Edlinger, et al.
Frontiers in Psychiatry|November 16, 2020
Premorbid Social Functioning and Affective Symptoms Predict Subjective Outcome Among Outpatients With SchizophreniaChristine M Hoertnagl, Alexandra Kaufmann, Nursen Yalcin-Siedentopf, et al.
Psychopharmacology|September 20, 2024
Exploring the role of orexins in the modulation of social rewardInês M Amaral, Sara Ouaidat, Laura Scheffauer, et al.
Bjpsych Open|September 23, 2024
Investigating patient eligibility for anti-amyloid monoclonal antibody treatment of Alzheimer's disease: real-world data from an Austrian psychiatric memory clinic populationMichaela Defrancesco, Elke R Gizewski, Stephanie Mangesius, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|August 19, 2025
Subjective well-being in early-phase schizophrenia patients using long-acting injectable versus oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)Anna-Theresa Schulze, Timo Schurr, Fabienne Post, et al.
The American Journal of Psychiatry|December 31, 2004
Osteoporosis in patients with schizophreniaMartina Hummer, Peter Malik, Rudolf W Gasser, et al.
Archives of Women'S Mental Health|October 15, 2020
Sex matters: stress perception and the relevance of resilience and perceived social support in emerging adultsNursen Yalcin-Siedentopf, Theresia Pichler, Anna-Sophia Welte, et al.
Pageof 14